In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback